Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aeterna Zentaris Inc T.AEZS

Alternate Symbol(s):  AEZS

Healthcare Biotechnology
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The... see more

Recent & Breaking News (TSX:AEZS)

18 Biggest Mid-Day Losers For Thursday

Benzinga.com  January 5, 2017

Mid-Day Market Update: Dow Falls Over 100 Points; Kohl's Shares Plummet

Benzinga.com  January 5, 2017

Mid-Morning Market Update: Markets Mixed; Walgreens Sales Miss Estimates

Benzinga.com  January 5, 2017

Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase 3 Trial of Macrilen™

Business Wire January 4, 2017

Aeterna Zentaris Reports Third Quarter 2016 Financial and Operating Results

Business Wire November 8, 2016

Aeterna Zentaris Announces Closing of US$7,560,000 Registered Direct Offering of Common Shares and Warrants

Business Wire November 1, 2016

Aeterna Zentaris to Announce Third Quarter 2016 Financial and Operating Results on November 8, 2016

Business Wire October 28, 2016

IIROC Trade Resumption - AEZ

Canada NewsWire October 27, 2016

IIROC Trade Resumption - Aeterna Zentaris Inc.

Newsfile October 27, 2016

Aeterna Zentaris Announces US$7,560,000 Registered Direct Offering of Common Shares and Warrants

Business Wire October 27, 2016

IIROC Trading Halt - AEZ

Canada NewsWire October 27, 2016

IIROC Trade Halt - Aeterna Zentaris Inc.

Newsfile October 27, 2016

Aeterna Zentaris Completes Patient Recruitment for Confirmatory Phase 3 Trial of Macrilen™

Business Wire October 26, 2016

18 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  October 14, 2016

10 Biggest Mid-Day Gainers For Thursday

Benzinga.com  October 13, 2016

Aeterna Zentaris and Specialised Therapeutics Asia Sign Exclusive License Agreement for the Potential Marketing of Zoptrex™ in Australia and New Zealand

Business Wire October 12, 2016

Aeterna Zentaris Announces Expiration of Remaining Series B Warrants

Business Wire September 14, 2016

Aeterna Zentaris to Present at Upcoming Aegis Capital Corp. 2016 Growth Conference in Las Vegas, Nevada

Business Wire September 12, 2016

Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York

Business Wire September 6, 2016

Aeterna Zentaris Reports Second Quarter 2016 Financial and Operating Results

Business Wire August 9, 2016